Many faculty members of the Department of Dermatology are actively engaged in clinical, translational, and basic research as principal investigators. Their work is and has been supported by the National Institutes of Health, US Department of Veterans Affairs, private foundations such as the Dermatology Foundation and the American Skin Association, and corporate industry.
Dermatology Center for Outcomes Research and Safety (DCORS)
The Dermatology Center for Outcomes Research and Safety (DCORS) serves as a central cooperative effort to provide infrastructure and support for dermatologic clinical, translational, and health services research. For more information, please click HERE
The Itch Translational Clinical Home at Emory (ITCH-E)
The mission of the Itch Translational Clinical Home at Emory is to create an interdisciplinary team of clinicians, translational researchers, basic researchers, and patients affected by itching in order to better understand mechanisms driving pruritus and to develop improved treatments for patients with itch. For more information, please click HERE
Jack L. Arbiser, MD, PHD
The Arbiser laboratory has a long history of development of small molecules as antiangiogenic and antitumor therapies. Dr. Jack Arbiser has both discovered natural products and synthesized novel small molecules. His laboratory discovered the antiangiogenic and in vivo antitumor properties of honokiol, and has synthesized honokiol analogs. In addition, his lab has synthesized Imipramine Blue, a novel NADPH oxidase inhibitor with systemic availability and antitumor efficacy. The Arbiser laboratory has recently pioneered a novel synthesis of solenopsin and solenopsin analogs, and has demonstrated that these analogs may act as ceramide analogs in demonstrating tumor suppressive activity. Finally, we have discovered and patented the antitumor properties of palladium complexes, including Tris DBA Palladium, with the intent to license them for clinical development. Learn More...
Ron J. Feldman, MD, PhD
Dr. Feldman's research focus is translational dermatology for improved understanding and therapeutics for patients with autoimmune blistering diseases. Dr. Feldman analyzes disease and treatment specific effects on quality of life. He has ongoing collaborative projects exploring immunologic mechanisms following B-cell depletion, alterations in cellular adhesion in pemphigus, and neutrophil biology in blister formation. For more information, please click HERE.
Brian P. Pollack, MD, PhD
Dr. Brian Pollack's
laboratory is interested in understanding how oncogenic signal transduction impacts the expression of immune system genes. Specifically, he are interested in how activation of the epidermal growth factor receptor impacts the expression of MHC class I and class II molecules. Further, the Pollack laboratory are also interested in defining in vivo how inhibitors of oncogenic kinases influence T cell mediated immune responses. Learn More...
Cassandra L. Quave, PhD
Dr. Cassandra Quave’s
research focuses on investigating the role of natural compounds in modulating bacterial quorum sensing and biofilm production, with an emphasis on microbes causing skin infection. In addition, Dr. Quave and the members of her lab, have developed a novel drug discovery platform based on botanical extracts used in traditional medicine for infectious and inflammatory disease. They focus on the discovery of new molecules for the treatment of bacterial and fungal infections, including those responsible for chronic itch (atopic dermatitis (eczema), candida infections, seborrheic dermatitis, jock itch, etc). Dr. Quave’s research has resulted in three patents for botanical inhibitors of microbial virulence, pathogenesis and growth. For more information, please visit the Quave lab website at etnobotanica.us
or on facebook